Immunological Applications of Stem Cells in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Current approaches aiming to cure type 1 diabetes (T1D) have made a negligible number of patients insulin-independent. In this review, we revisit the role of stem cell (SC)-based applications in curing T1D. The optimal therapeutic approach for T1D should ideally preserve the remaining β-cells, restore β-cell function, and protect the replaced insulin-producing cells from autoimmunity. SCs possess immunological and regenerative properties that could be harnessed to improve the treatment of T1D; indeed, SCs may reestablish peripheral tolerance toward β-cells through reshaping of the immune response and inhibition of autoreactive T-cell function. Furthermore, SC-derived insulin-producing cells are capable of engrafting and reversing hyperglycemia in mice. Bone marrow mesenchymal SCs display a hypoimmunogenic phenotype as well as a broad range of immunomodulatory capabilities, they have been shown to cure newly diabetic nonobese diabetic (NOD) mice, and they are currently undergoing evaluation in two clinical trials. Cord blood SCs have been shown to facilitate the generation of regulatory T cells, thereby reverting hyperglycemia in NOD mice. T1D patients treated with cord blood SCs also did not show any adverse reaction in the absence of major effects on glycometabolic control. Although hematopoietic SCs rarely revert hyperglycemia in NOD mice, they exhibit profound immunomodulatory properties in humans; newly hyperglycemic T1D patients have been successfully reverted to normoglycemia with autologous nonmyeloablative hematopoietic SC transplantation. Finally, embryonic SCs also offer exciting prospects because they are able to generate glucose-responsive insulin-producing cells. Easy enthusiasm should be mitigated mainly because of the potential oncogenicity of SCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 1×
“MSCs are multipotent cells localized in several tissues including CB, bone marrow, and adipose tissue (113); however, we will primarily refer to the cell derived from the most widely used source: the bone marrow-derived MSCs.”
BackgroundWarren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854 · cited 1×
“A European study based on the EURODIAB register, which evaluated a population from 17 countries between 1989 and 2003, confirmed 29,311 new cases of T1D and projected a doubling of new cases of T1D in European children between 2005 and 2020 (4).”
BackgroundKroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 2×
“Novocell scientists have developed a method to generate IPCs from human ESCs on a large-scale (54, 55) and have suggested encapsulation of these IPCs.”
BackgroundMethodHuman mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilić, J., Pekarik, V., Tiscornia, G., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1503 · Cited by 1,423 · cited 1×
“iPS have been obtained from: 1) human somatic cells including keratinocytes (224, 225), dermal skin fibroblasts (214, 225–228), lung fibroblasts (228), astrocytes (229), and T cells (230, 231); 2) human ASCs including bone marrow MSCs (228), CD34 bone marrow SCs (232), fetal neural SCs (233), and adipose stromal cells…”
BackgroundGenetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 1×
“Historically, approaches aiming to cure T1D have made a negligible number of patients insulin-independent (10).”
BackgroundRecovery from diabetes in mice by β cell regeneration
Nir, T., Melton, D. A., & Dor, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32959 · Cited by 595 · cited 1×
“A successful approach should preserve the remaining -cells, restore -cell function, and protect the replaced IPCs from autoimmune destruction (11, 12).”
BackgroundSeki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.003 · Cited by 584 · cited 1×
“iPS have been obtained from: 1) human somatic cells including keratinocytes (224, 225), dermal skin fibroblasts (214, 225–228), lung fibroblasts (228), astrocytes (229), and T cells (230, 231); 2) human ASCs including bone marrow MSCs (228), CD34 bone marrow SCs (232), fetal neural SCs (233), and adipose stromal cells…”
BackgroundVoltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., et al. (2007) · JAMA · doi:10.1001/jama.297.14.1568 · Cited by 573 · cited 3×
“tive in limited groups of newly diagnosed patients (173).”
BackgroundInfluentialSelf-citationCouri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402 · cited 3×
“Another study reported only a minor immuneresponse against human ESCs in mice conditioned to carry human leukocytes (39), confirming the lack of expression of MHC class II, as well as low expression of costimulatory molecules and MHC class I (39).”
BackgroundAdult human mesenchymal stem cell as a target for neoplastic transformation
Serakinci, N., Guldberg, P., Burns, J. S., Abdallah, B., Schrødder, H., Jensen, T., & Kassem, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207651 · Cited by 350
Martin, F. T., Dwyer, R. M., Kelly, J., Khan, S., Murphy, J. M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F. P., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0734-1 · Cited by 290 · cited 1×
“epithelial to mesenchymal transition (125) or through the”
BackgroundGeneration of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors
Narsinh, K. H., Jia, F., Robbins, R. C., Kay, M. A., Longaker, M. T., & Wu, J. C. (2011) · Nature Protocols · doi:10.1038/nprot.2010.173 · Cited by 214 · cited 1×
“iPS have been obtained from: 1) human somatic cells including keratinocytes (224, 225), dermal skin fibroblasts (214, 225–228), lung fibroblasts (228), astrocytes (229), and T cells (230, 231); 2) human ASCs including bone marrow MSCs (228), CD34 bone marrow SCs (232), fetal neural SCs (233), and adipose stromal cells…”
BackgroundInduced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa
Tolar, J., Xia, L., Riddle, M. J., Lees, C. J., Eide, C. R., McElmurry, R. T., Titeux, M., Osborn, M. J., Lund, T. C., Hovnanian, A., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.346 · Cited by 155 · cited 1×
“iPS have been obtained from: 1) human somatic cells including keratinocytes (224, 225), dermal skin fibroblasts (214, 225–228), lung fibroblasts (228), astrocytes (229), and T cells (230, 231); 2) human ASCs including bone marrow MSCs (228), CD34 bone marrow SCs (232), fetal neural SCs (233), and adipose stromal cells…”
Background
Cited by
Kidney Transplantation in Children
Dharnidharka, V. R., Fiorina, P., & Harmon, W. E. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314376 · Cited by 265
Self-citationMechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
D’Addio, F., Valderrama Vasquez, A., Ben Nasr, M., Franek, E., Zhu, D., Li, L., Ning, G., Snarski, E., & Fiorina, P. (2014) · Diabetes · doi:10.2337/db14-0295 · Cited by 160
Self-citationAraújo, A. B., Salton, G. D., Furlan, J. M., Schneider, N., Angeli, M. H., Laureano, Á. M., Silla, L., Passos, E. P., & Paz, A. H. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.03.001 · Cited by 83
Metadata
- Authors
- Fiorina, P., Voltarelli, J., & Zavazava, N.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2011-08-23
- Volume
- 32
- Issue
- 6
- Pages
- 725-754
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2011644642
- Cited by
- 135
- References
- 19
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.